Portola Pharmaceuticals Inc Quick Ratio (PTLA) starting from the first quarter 2020 to first quarter 2019, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Portola Pharmaceuticals inc   (NASDAQ: PTLA)

Portola Pharmaceuticals Inc 's Quick Ratio

PTLA's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Current Liabilities decreased faster than Portola Pharmaceuticals Inc 's Cash & cash equivalent, this led to improvement in Portola Pharmaceuticals Inc 's Quick Ratio to 4.56, Quick Ratio remained below Portola Pharmaceuticals inc average.

Within Major Pharmaceutical Preparations industry 228 other companies have achieved higher Quick Ratio than Portola Pharmaceuticals Inc in first quarter 2020. While Quick Ratio total ranking has improved so far during the Q1 2020 to 698, from total ranking in the fourth quarter 2019 at 741.

Explain Quick Ratio?
How much Cash & cash equivalents PTLA´s has?
What are PTLA´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

PTLA Quick Ratio (Mar 31 2020)
Q1		 (Dec 31 2019)
Q4		 (Sep 30 2019)
Q3		 (Jun 30 2019)
Q2		 (Mar 31 2019)
Q1
Y / Y Current Liabilities Change 9.04 % 48.42 % 43.24 % 17.78 % 28.38 %
Y / Y Cash & cash equivalent Change 13.2 % 36.06 % 29.64 % -36.64 % -20.62 %
Quick Ratio MRQ 4.56 4.22 5.49 3.28 4.39
PTLA's Total Ranking # 698 # 741 # 593 # 803 # 580
Seq. Current Liabilities Change -21.4 % 17.06 % 3.78 % 14.19 % 6.99 %
Seq. Cash & cash equivalent Change -15.15 % -9.85 % 73.78 % -14.84 % 1.99 %



Quick Ratio first quarter 2020 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 229
Healthcare Sector # 356
Overall Market # 698


Quick Ratio Statistics
High Average Low
24.41 7.73 3.28
(Mar 31 2015)   (Jun 30 2019)




Financial Statements
Portola Pharmaceuticals Inc 's Current Liabilities $ 80 Millions Visit PTLA's Balance sheet
Portola Pharmaceuticals Inc 's Cash & cash equivalent $ 367 Millions Visit PTLA's Balance sheet
Source of PTLA's Sales Visit PTLA's Sales by Geography


Cumulative Portola Pharmaceuticals Inc 's Quick Ratio

PTLA's Quick Ratio for the trailling 12 Months

PTLA Quick Ratio

 (Mar 31 2020)
12 Months		 (Dec 31 2019)
12 Months		 (Sep 30 2019)
12 Months		 (Jun 30 2019)
12 Months		 (Mar 31 2019)
12 Months
Y / Y Current Liabilities TTM Growth 28.76 % 34.29 % 11.92 % -0.55 % 9.79 %
Y / Y Cash & cash equivalent TTM Growth 7.42 % -1.27 % -36.24 % -46.13 % -45.2 %
Quick Ratio TTM 4.39 4.35 4.45 4.47 5.26
Total Ranking TTM # 4534 # 4561 # 266 # 267 # 271
Seq. Current Liabilities TTM Growth 1.92 % 10.62 % 9.16 % 4.62 % 6.3 %
Seq. Cash & cash equivalent TTM Growth 2.83 % 8.2 % 8.52 % -11.02 % -5.5 %

Quick ratio ranking by company, industry and sector >> Back to PTLA Financial Strength Comparisons >> Go to Compare PTLA Quick Ratio to its Competitors

On the trailing twelve months basis PTLA Cash & cash equivalent increased by 13.2 % in Q1 2020 year on year, faster than Current Liabilities, this led to increase in in Portola Pharmaceuticals Inc 's Quick Ratio to 4.39, Quick Ratio remained below PTLA average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 479 other companies have achieved higher Quick Ratio than Portola Pharmaceuticals Inc . While Quick Ratio overall ranking has improved so far to 4534, from total ranking during the twelve months ending fourth quarter 2019 at 4561.

Explain Quick Ratio?
How much Cash & cash equivalents PTLA´s has?
What are PTLA´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 480
Healthcare Sector # 910
Within the Market # 4534


trailing twelve months Quick Ratio Statistics
High Average Low
8.38 6.44 4.35
(Dec 31 2015)   (Dec 31 2019)




Companies with similar Quick Ratio in the quarter ending Mar 31 2020, within Major Pharmaceutical Preparations Industry Quick RatioMar 31 2020 MRQ Cash & cash equivalentMar 31 2020 MRQ Current Liabilities
Mirati Therapeutics Inc   12.54 $ 695.360  Millions$ 55.450  Millions
Y mabs Therapeutics inc   12.52 $ 185.774  Millions$ 14.843  Millions
Medicenna Therapeutics Corp.  12.51 $ 16.072  Millions$ 1.285  Millions
Sage Therapeutics Inc   12.40 $ 872.757  Millions$ 70.360  Millions
Kala Bio inc   12.36 $ 196.456  Millions$ 15.898  Millions
Aravive Inc   12.24 $ 60.700  Millions$ 4.959  Millions
Nucana Plc  12.22 $ 99.557  Millions$ 8.149  Millions
Lexaria Bioscience Corp   12.06 $ 0.764  Millions$ 0.063  Millions
Astria Therapeutics Inc   12.01 $ 55.103  Millions$ 4.590  Millions
Vanda Pharmaceuticals Inc   11.99 $ 312.326  Millions$ 26.045  Millions
Assembly Biosciences Inc   11.78 $ 249.129  Millions$ 21.146  Millions
Mirum Pharmaceuticals Inc   11.78 $ 159.531  Millions$ 13.548  Millions
Akcea Therapeutics Inc   11.60 $ 421.302  Millions$ 36.332  Millions
Kiniksa Pharmaceuticals International Plc  11.57 $ 204.206  Millions$ 17.653  Millions
Ngm Biopharmaceuticals Inc   11.54 $ 328.469  Millions$ 28.462  Millions
Tonix Pharmaceuticals Holding Corp   11.53 $ 30.672  Millions$ 2.660  Millions
Oncolytics Biotech Inc   11.52 $ 23.914  Millions$ 2.075  Millions
Bio path Holdings inc   11.27 $ 17.891  Millions$ 1.587  Millions
Guardion Health Sciences Inc   11.22 $ 12.890  Millions$ 1.148  Millions
Provention Bio Inc   11.10 $ 76.629  Millions$ 6.903  Millions
Ascendis Pharma A  11.07 $ 654.659  Millions$ 59.140  Millions
89bio Inc   10.98 $ 85.532  Millions$ 7.787  Millions
Pfenex Inc   10.95 $ 65.602  Millions$ 5.991  Millions
Atossa Therapeutics Inc   10.77 $ 9.461  Millions$ 0.879  Millions
Phasebio Pharmaceuticals Inc.  10.61 $ 59.441  Millions$ 5.604  Millions
Crinetics Pharmaceuticals Inc   10.48 $ 112.802  Millions$ 10.760  Millions
Alaunos Therapeutics Inc   10.31 $ 171.002  Millions$ 16.579  Millions
Dianthus Therapeutics Inc   10.27 $ 130.406  Millions$ 12.703  Millions
Capricor Therapeutics inc   10.20 $ 13.217  Millions$ 1.296  Millions
Sarepta Therapeutics Inc   10.08 $ 2,171.152  Millions$ 215.356  Millions

Date modified: 2026-09-08T15:09:56+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.